Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Peripheral Plasma Micro-RNA and Proteomics Mapping in Depressive Patients, Treated With SSRI Medications (MIRPROT)

This study has been terminated.
(Insufficient microRNA for the analysis)
Information provided by (Responsible Party):
Amichai Hareven, HaEmek Medical Center, Israel Identifier:
First received: September 5, 2012
Last updated: June 18, 2015
Last verified: June 2015

A pilot study of mapping the peripheral plasma micro-RNA and proteomics patterns in depressive patients, treated with SSRI medications. It is an observational clinical bio-markers laboratory controlled research with no device.

The research includes two groups; one for patients diagnosed of having depression, and will get a standard SSRI medication regimen. Second group is for control subjects without depression. An option for a third group is planned to include first degree relatives of the depressed patients. After giving their informed consents, subjects and patients will go through standard clinical psychiatric interview, and routine clinical lab tests. Clinical standard, specific depression and anxiety questionnaires will be held at four follow-up meetings: at start; after 2 weeks; 4 weeks; and 10 weeks. Subjects and patients will be asked to give blood samples at these points of time for the lab processing: Complete plasma proteomics and specific micro-RNA levels.


Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Peripheral Plasma Micro-RNA and Proteomics Mapping in Depressive Patients, Treated With SSRI Medications.

Resource links provided by NLM:

Further study details as provided by HaEmek Medical Center, Israel:

Primary Outcome Measures:
  • Depressive symptoms remission or response rates, under usual SSRI treatment. [ Time Frame: 10 weeks of follow up ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA
Subjects and patients will be asked to give blood samples at 4 points of time for the lab processing: micro-RNA and proteome profiling/

Enrollment: 17
Study Start Date: November 2011
Study Completion Date: February 2014
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Depressed Patients
Patients: Group of patients that are diagnosed for having depression, and are suitable for SSRI treatment.
Non-Depressed Controls
Controls: Volunteers that had clinical screening with no depression diagnosis.
Patients Relatives
Patient Relatives (Optional group for later stage): First degree relatives with no depression diagnosis.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients at community or hospital settings. Patients were clinically evaluated for suspected depression.

Inclusion Criteria:

  • Depressed patients,over 18 yo
  • Untreated with SSRI, in the last 3 months

Exclusion Criteria:

  • Bipolar patients or another major psychopathology
  • Depressive disorder clearly due to general medical condition, or drug related
  • BMI under 18.5 or above 40
  • Pregnant patients
  • Active suicidality
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01681407

HaEmek Medical Center
Afula, Israel
Sponsors and Collaborators
HaEmek Medical Center, Israel
  More Information

Responsible Party: Amichai Hareven, Dr Amichai Hareven, HaEmek Medical Center, Israel Identifier: NCT01681407     History of Changes
Other Study ID Numbers: EMC-07411-CTIL 
Study First Received: September 5, 2012
Last Updated: June 18, 2015
Health Authority: Israel: Ministry of Health

Keywords provided by HaEmek Medical Center, Israel:
Selective Serotonin Reuptake Inhibitors

Additional relevant MeSH terms:
Behavioral Symptoms
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs processed this record on October 21, 2016